Press "Enter" to skip to content

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months – BioSpace

admin 0

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months  BioSpace
“pancreatic cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *